DENTSPLY SIRONA INC (XRAY) Fundamental Analysis & Valuation

NASDAQ:XRAY • US24906P1093

11.8 USD
-0.93 (-7.31%)
At close: Mar 12, 2026
11.85 USD
+0.05 (+0.42%)
After Hours: 3/12/2026, 8:17:05 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XRAY fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to XRAY. XRAY was compared to 184 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

4

1. XRAY Profitability Analysis

1.1 Basic Checks

  • XRAY had positive earnings in the past year.
  • In the past year XRAY had a positive cash flow from operations.
  • In the past 5 years XRAY reported 4 times negative net income.
  • Each year in the past 5 years XRAY had a positive operating cash flow.
XRAY Yearly Net Income VS EBIT VS OCF VS FCFXRAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B -1.5B

1.2 Ratios

  • XRAY has a Return On Assets of -11.01%. This is comparable to the rest of the industry: XRAY outperforms 58.15% of its industry peers.
  • XRAY has a Return On Equity (-44.66%) which is in line with its industry peers.
  • XRAY's Return On Invested Capital of 4.89% is fine compared to the rest of the industry. XRAY outperforms 75.54% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 9.18%.
  • The last Return On Invested Capital (4.89%) for XRAY is above the 3 year average (4.23%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -11.01%
ROE -44.66%
ROIC 4.89%
ROA(3y)-9.54%
ROA(5y)-7.32%
ROE(3y)-31.84%
ROE(5y)-22.45%
ROIC(3y)4.23%
ROIC(5y)4.67%
XRAY Yearly ROA, ROE, ROICXRAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30 -40

1.3 Margins

  • XRAY's Operating Margin of 6.88% is fine compared to the rest of the industry. XRAY outperforms 71.74% of its industry peers.
  • In the last couple of years the Operating Margin of XRAY has declined.
  • XRAY has a Gross Margin (50.00%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
Industry RankSector Rank
OM 6.88%
PM (TTM) N/A
GM 50%
OM growth 3Y-9.52%
OM growth 5Y-3.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.67%
GM growth 5Y-0.36%
XRAY Yearly Profit, Operating, Gross MarginsXRAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XRAY Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), XRAY is destroying value.
  • The number of shares outstanding for XRAY has been increased compared to 1 year ago.
  • Compared to 5 years ago, XRAY has less shares outstanding
  • XRAY has a worse debt/assets ratio than last year.
XRAY Yearly Shares OutstandingXRAY Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
XRAY Yearly Total Debt VS Total AssetsXRAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 0.95, we must say that XRAY is in the distress zone and has some risk of bankruptcy.
  • XRAY has a Altman-Z score of 0.95. This is comparable to the rest of the industry: XRAY outperforms 49.46% of its industry peers.
  • XRAY has a debt to FCF ratio of 22.38. This is a negative value and a sign of low solvency as XRAY would need 22.38 years to pay back of all of its debts.
  • XRAY's Debt to FCF ratio of 22.38 is fine compared to the rest of the industry. XRAY outperforms 69.57% of its industry peers.
  • A Debt/Equity ratio of 1.50 is on the high side and indicates that XRAY has dependencies on debt financing.
  • XRAY has a worse Debt to Equity ratio (1.50) than 78.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.5
Debt/FCF 22.38
Altman-Z 0.95
ROIC/WACC0.58
WACC8.46%
XRAY Yearly LT Debt VS Equity VS FCFXRAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 1.51 indicates that XRAY should not have too much problems paying its short term obligations.
  • XRAY has a Current ratio of 1.51. This is in the lower half of the industry: XRAY underperforms 74.46% of its industry peers.
  • XRAY has a Quick Ratio of 1.03. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
  • XRAY has a Quick ratio of 1.03. This is in the lower half of the industry: XRAY underperforms 77.17% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.03
XRAY Yearly Current Assets VS Current LiabilitesXRAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. XRAY Growth Analysis

3.1 Past

  • The earnings per share for XRAY have decreased by -4.79% in the last year.
  • The Earnings Per Share has been decreasing by -2.34% on average over the past years.
  • The Revenue has decreased by -2.98% in the past year.
  • XRAY shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.96% yearly.
EPS 1Y (TTM)-4.79%
EPS 3Y-8.57%
EPS 5Y-2.34%
EPS Q2Q%3.85%
Revenue 1Y (TTM)-2.98%
Revenue growth 3Y-2.1%
Revenue growth 5Y1.96%
Sales Q2Q%6.19%

3.2 Future

  • XRAY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.14% yearly.
  • XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.31% yearly.
EPS Next Y-7.79%
EPS Next 2Y0.27%
EPS Next 3Y3.98%
EPS Next 5Y4.14%
Revenue Next Year-1.64%
Revenue Next 2Y0.13%
Revenue Next 3Y0.96%
Revenue Next 5Y1.31%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XRAY Yearly Revenue VS EstimatesXRAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B 4B
XRAY Yearly EPS VS EstimatesXRAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0.5 1 1.5 2 2.5

More info and screens

Find the best growth stocksShow best growing peers

7

4. XRAY Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 7.42 indicates a rather cheap valuation of XRAY.
  • XRAY's Price/Earnings ratio is rather cheap when compared to the industry. XRAY is cheaper than 95.65% of the companies in the same industry.
  • XRAY's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 25.71.
  • A Price/Forward Earnings ratio of 8.05 indicates a reasonable valuation of XRAY.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 96.74% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, XRAY is valued rather cheaply.
Industry RankSector Rank
PE 7.42
Fwd PE 8.05
XRAY Price Earnings VS Forward Price EarningsXRAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • 95.11% of the companies in the same industry are more expensive than XRAY, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, XRAY is valued cheaply inside the industry as 83.15% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.66
EV/EBITDA 7.51
XRAY Per share dataXRAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.27%
EPS Next 3Y3.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

7

5. XRAY Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 5.17%, XRAY is a good candidate for dividend investing.
  • XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.21. XRAY pays more dividend than 99.46% of the companies in the same industry.
  • XRAY's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 5.17%

5.2 History

  • The dividend of XRAY is nicely growing with an annual growth rate of 9.95%!
  • XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
  • XRAY has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)9.95%
Div Incr Years6
Div Non Decr Years30
XRAY Yearly Dividends per shareXRAY Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • XRAY has negative earnings and hence a negative payout ratio. The dividend may be in danger.
  • XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-21.4%
EPS Next 2Y0.27%
EPS Next 3Y3.98%
XRAY Yearly Income VS Free CF VS DividendXRAY Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M -1B -1.5B

More info and screens

Find the best dividend stocksShow peers with best dividend

XRAY Fundamentals: All Metrics, Ratios and Statistics

DENTSPLY SIRONA INC

NASDAQ:XRAY (3/12/2026, 8:17:05 PM)

After market: 11.85 +0.05 (+0.42%)

11.8

-0.93 (-7.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners104.18%
Inst Owner Change-3.83%
Ins Owners0.22%
Ins Owner Change5.33%
Market Cap2.36B
Revenue(TTM)3.68B
Net Income(TTM)-598.00M
Analysts70
Price Target13.22 (12.03%)
Short Float %7.41%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield 5.17%
Yearly Dividend0.64
Dividend Growth(5Y)9.95%
DP-21.4%
Div Incr Years6
Div Non Decr Years30
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.91%
Min EPS beat(2)-19.03%
Max EPS beat(2)-4.78%
EPS beat(4)2
Avg EPS beat(4)5.76%
Min EPS beat(4)-19.03%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-2.22%
EPS beat(12)5
Avg EPS beat(12)0.84%
EPS beat(16)7
Avg EPS beat(16)2.02%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.16%
Max Revenue beat(2)1.63%
Revenue beat(4)2
Avg Revenue beat(4)-0.11%
Min Revenue beat(4)-1.67%
Max Revenue beat(4)1.63%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)5
Avg Revenue beat(12)-0.96%
Revenue beat(16)6
Avg Revenue beat(16)-1.46%
PT rev (1m)1.68%
PT rev (3m)1.83%
EPS NQ rev (1m)-18.62%
EPS NQ rev (3m)-21.01%
EPS NY rev (1m)-5.83%
EPS NY rev (3m)-9.18%
Revenue NQ rev (1m)-5.07%
Revenue NQ rev (3m)-4.95%
Revenue NY rev (1m)-2.32%
Revenue NY rev (3m)-2.38%
Valuation
Industry RankSector Rank
PE 7.42
Fwd PE 8.05
P/S 0.64
P/FCF 22.66
P/OCF 10.03
P/B 1.76
P/tB N/A
EV/EBITDA 7.51
EPS(TTM)1.59
EY13.47%
EPS(NY)1.47
Fwd EY12.43%
FCF(TTM)0.52
FCFY4.41%
OCF(TTM)1.18
OCFY9.97%
SpS18.42
BVpS6.7
TBVpS-3.92
PEG (NY)N/A
PEG (5Y)N/A
Graham Number15.49
Profitability
Industry RankSector Rank
ROA -11.01%
ROE -44.66%
ROCE 6.19%
ROIC 4.89%
ROICexc 5.32%
ROICexgc 12.2%
OM 6.88%
PM (TTM) N/A
GM 50%
FCFM 2.83%
ROA(3y)-9.54%
ROA(5y)-7.32%
ROE(3y)-31.84%
ROE(5y)-22.45%
ROIC(3y)4.23%
ROIC(5y)4.67%
ROICexc(3y)4.53%
ROICexc(5y)4.96%
ROICexgc(3y)13.19%
ROICexgc(5y)19.09%
ROCE(3y)5.56%
ROCE(5y)6.04%
ROICexgc growth 3Y-15.1%
ROICexgc growth 5Y-11.06%
ROICexc growth 3Y3.36%
ROICexc growth 5Y12.36%
OM growth 3Y-9.52%
OM growth 5Y-3.69%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.67%
GM growth 5Y-0.36%
F-Score5
Asset Turnover0.68
Health
Industry RankSector Rank
Debt/Equity 1.5
Debt/FCF 22.38
Debt/EBITDA 3.33
Cap/Depr 37.22%
Cap/Sales 3.56%
Interest Coverage 3.83
Cash Conversion 38.84%
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.03
Altman-Z 0.95
F-Score5
WACC8.46%
ROIC/WACC0.58
Cap/Depr(3y)44.08%
Cap/Depr(5y)43.74%
Cap/Sales(3y)4.02%
Cap/Sales(5y)3.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.79%
EPS 3Y-8.57%
EPS 5Y-2.34%
EPS Q2Q%3.85%
EPS Next Y-7.79%
EPS Next 2Y0.27%
EPS Next 3Y3.98%
EPS Next 5Y4.14%
Revenue 1Y (TTM)-2.98%
Revenue growth 3Y-2.1%
Revenue growth 5Y1.96%
Sales Q2Q%6.19%
Revenue Next Year-1.64%
Revenue Next 2Y0.13%
Revenue Next 3Y0.96%
Revenue Next 5Y1.31%
EBIT growth 1Y10%
EBIT growth 3Y-11.42%
EBIT growth 5Y-1.8%
EBIT Next Year18.41%
EBIT Next 3Y10.01%
EBIT Next 5Y10.04%
FCF growth 1Y-62.99%
FCF growth 3Y-34.38%
FCF growth 5Y-28.64%
OCF growth 1Y-49.02%
OCF growth 3Y-23.11%
OCF growth 5Y-18.39%

DENTSPLY SIRONA INC / XRAY FAQ

What is the ChartMill fundamental rating of DENTSPLY SIRONA INC (XRAY) stock?

ChartMill assigns a fundamental rating of 4 / 10 to XRAY.


What is the valuation status for XRAY stock?

ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.


How profitable is DENTSPLY SIRONA INC (XRAY) stock?

DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.


Can you provide the PE and PB ratios for XRAY stock?

The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.42 and the Price/Book (PB) ratio is 1.76.


Can you provide the dividend sustainability for XRAY stock?

The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -21.4%.